Drug intelligence / Profile preview

house dust mite PLGA nanoparticle vaccine

Development stage: Preclinical
Lead developer: Institute of Dermatology, Chinese Academy of Medical Sciences
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

The house dust mite PLGA nanoparticle vaccine is an experimental allergen-specific immunotherapy (AIT) candidate developed by the Institute of Dermatology, Chinese Academy of Medical Sciences. It consists of house dust mite (HDM) allergens encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The vaccine is specifically designed to target Langerhans cells in the skin via the Langerin (CD207) receptor. By delivering HDM allergens directly to these antigen-presenting cells, the vaccine aims to induce immune tolerance and modulate the allergic response, specifically for the prevention and treatment of atopic dermatitis. This approach leverages the biodegradable and biocompatible properties of PLGA to provide a controlled release of the allergen and enhance the safety and efficacy of traditional immunotherapy.

Other names: HDM-PLGA vaccineHouse Dust Mite-PLGA Vaccine Targeting Langerhans Cells Through Langerin

Targets

Major histocompatibility complex class II presenting Dermatophagoides pteronyssinus allergen 2 peptidesDer p 2-specific B-cell receptor (Der p 2-specific BCR)CD4+ T-cell receptor specific for Dermatophagoides pteronyssinus allergen 2–MHC class II complexCLEC9A (C-type lectin domain family 9 member A)

Beyond the preview

Go deeper on house dust mite PLGA nanoparticle vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on house dust mite PLGA nanoparticle vaccine.

Explore the full profile